After Hours
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility.
Stocks Info
KalVista Pharmaceuticals Inc is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. The current market capitalization of KalVista Pharmaceuticals Inc is $707.35M. A total of 1.42 million shares were traded on the day, compared to an average of 1.21M shares.
In the most recent transaction, Sweeny Nicole sold 1,480 shares of KALV for 13.42 per share on Aug 25 ’25. After the transaction, the Chief Commercial Officer now owns 32,291 company shares. In a previous transaction on Aug 25 ’25, Yea Christopher sold 1,954 shares at 13.42 per share. KALV shares that CHIEF DEVELOPMENT OFFICER owns now total 132,052.
Among the insiders who sold shares, Audhya Paul K. disposed of 2,336 shares on Aug 25 ’25 at a per-share price of $13.42. This resulted in the CHIEF MEDICAL OFFICER holding 122,505 shares of KALV after the transaction. In another insider transaction, Sweeny Nicole sold 1,864 shares at $13.22 per share on Aug 22 ’25. Company shares held by the Chief Commercial Officer now total 28,771.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. In terms of 52-week highs and lows, KALV has a high of $16.32 and a low of $7.30.
As of this writing, KALV has an earnings estimate of -$0.96 per share for the current quarter. EPS was calculated based on a consensus of 7.0 estimates, with a high estimate of -$0.72 per share and a lower estimate of -$1.28. The company reported an EPS of -$0.87 in the last quarter
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. KALV’s latest balance sheet shows that the firm has $166.20M in Cash & Short Term Investments as of fiscal 2022. There were $8.19M in debt and $11.58M in liabilities at the time. Its Book Value Per Share was $1.92, while its Total Shareholder’s Equity was $185.09M.
Analysts Opinion
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for KALV is Buy with a score of 4.73.
